Electrotherapy System Market size worth $ 1587.04 Billion, Globally, by 2031 at 4.39% CAGR – Report By Verified Market Research®
April 24, 2024 10:15 ET
|
Verified Market Research
Jersey City, New Jersey, April 24, 2024 (GLOBE NEWSWIRE) -- The Global Electrotherapy System Market is projected to grow at a CAGR of 4.39% from 2024 to 2031, according to a new report published by...
Meet Our Nation’s Next Generation of Leaders, Volunteer at FBLA
April 24, 2024 10:10 ET
|
Future Business Leaders of America
Reston, Virginia, April 24, 2024 (GLOBE NEWSWIRE) -- Future Business Leaders of America, Inc. (FBLA), the nation’s largest career and technical student organization focused solely on business,...
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
April 24, 2024 10:09 ET
|
Cullinan Therapeutics, Inc.
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that...
6K Energy Announces IRA Compliant LFP and NMC Lithium-Ion Cathode Active Material (CAM) for North American Battery Production
April 24, 2024 10:07 ET
|
6K
6K Energy Announces IRA Compliant LFP and NMC Lithium-Ion Cathode Active Material (CAM) for North American Battery Production.
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
April 24, 2024 10:05 ET
|
Regeneron Pharmaceuticals, Inc.
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination...
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:05 ET
|
Werewolf Therapeutics, Inc.
Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) --...
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
April 24, 2024 10:05 ET
|
Medicenna Therapeutics Corp.
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity...
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:02 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective...
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:01 ET
|
Cue Biopharma, Inc.
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...
MAKE, Casper Partners With D3 To Apply For .cspr Top-Level Domain
April 24, 2024 10:00 ET
|
D3 Global
Las Vegas, Nevada, April 24, 2024 (GLOBE NEWSWIRE) -- MAKE, a blockchain technology innovation firm, with the support of the Casper Association, have announced an exclusive partnership...